Minovia Therapeutics News
11 articles
growth-positive
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
Minovia Therapeutics Ltd., a clinical-stage biotechnology company, has entered into a definitive business combination agreement with Launch One Acquisition Corp., a special purpose acquisition company. This transaction will create a publicly traded entity focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) to address diseases driven by mitochondrial dysfunction. The business combination is expected to close in the fourth quarter of 2025, providing Minovia with additional capital to accelerate its growth and development pipeline. The transaction assigns Minovia a pre-money equity valuation of $180 million, with additional PIPE investments anticipated. Minovias lead product, MNV-201, is in Phase 2 trials for Pearson Syndrome and has received FDA Fast Track Designation.
Public TradingPIPE/POInvestment
growth-positive
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
Minovia Therapeutics Ltd, a clinical-stage biopharmaceutical company, has announced that the FDA has cleared its second Investigational New Drug (IND) application for MNV-201, a mitochondrial cell therapy product. This clearance allows Minovia to initiate a Phase II clinical trial for pediatric patients with Pearson Syndrome, a severe mitochondrial disease. The trial aims to evaluate the safety and efficacy of MNV-201, focusing on improving growth and quality of life. The FDAs clearance marks a significant milestone for Minovia, enabling them to advance their allogeneic mitochondrial therapy approach. The study will enroll additional patients and is expected to provide insights into the potential benefits of MNV-201 for this patient population.
Product StageFDA approved/pending approval
growth-positive
New cell therapy may be key to curing disease - ISRAEL21c
Minovia Therapeutics, an Israeli company, is developing mitochondrial augmentation therapy (MAT) to treat rare mitochondrial diseases. The therapy involves enriching hematopoietic stem cells with healthy mitochondria and injecting them back into patients. The company has conducted successful trials on children with Pearson syndrome, a bone marrow disorder. The children showed improvement in aerobic function, weight gain, and strength. Minovia is now developing an off-the-shelf product using mitochondria from donated placentas. The first indication for the product is still Pearson syndrome, but the company plans to expand to other indications. Minovia intends to collaborate with big pharma companies and has already partnered with Astellas Pharma. The company has received investments totaling nearly $30 million and holds 70 patents. It has 46 employees, mostly female.
CustomersPartnersInvestmentManagement Changes
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
growth-positive
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
Minovia Therapeutics and Astellas Pharma have announced a global strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction. The partnership aims to accelerate the creation of allogeneic mitochondrial cell therapy programs, with the two companies jointly researching cell therapy program candidates. Under the terms of the agreement, Minovia will receive an upfront cash payment of $20M USD from Astellas. If Astellas develops and commercializes product candidates for diseases caused by mitochondrial dysfunction, Minovia could receive up to $420M USD per product in future development, regulatory and commercial milestone payments from Astellas.
PartnersInvestment
N/A
Mitochondrial biotech Minovia Therapeutics nabs biopharma veteran Jacobs as new chief medical officer
The article discusses the terms of use and privacy policy of Questex LLC.
Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O'Donnell as Global Head of Manufacturing and Supply Chain
Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th
growth-positive
Minovia Therapeutics Leases 4,600 SF in Woburn - Boston Real Estate Times
Minovia Therapeutics, an international life sciences firm, is expanding its U.S. operations by opening a 4,600-square-foot facility in Woburns technology cluster. The company, which specializes in developing cell therapy for rare mitochondrial diseases, will commence its GMP manufacturing at the new facility. The location and buildout of the space are ideal for Minovias operations. The expansion signifies growth for the company.
Expand
growth-positive
New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics' Natalie Yivgi Ohana BioSpace
Minovia Therapeutics has dosed the first patient in a Phase I/II clinical trial for Pearson syndrome, a rare mitochondrial disease. The company is using its Mitochondrial Augmentation Therapy (MAT) platform, which aims to increase the level of normal mitochondrial DNA using autologous stem cells enriched with normal mitochondria. The trial will evaluate the safety and clinical effects of the companys autologous CD34+ cells enriched with blood-derived mitochondria in pediatric patients. Minovia is also planning to open an office in Cambridge, Massachusetts and hire 20 employees by the end of 2020. The company is focused on partnering with academic and medical institutions and developing new therapies for mitochondrial diseases.
Customers
growth-positive
Minovia Announces Dosing of Patient in First Mitochondrial Cell Therapy Trial for the Treatment of Pearson Syndrome BioSpace
Minovia Therapeutics has announced the dosing of the first patient in a Phase I/II clinical trial of its Mitochondrial Augmentation Therapy (MAT) for the treatment of Pearson syndrome. The trial, which is the first ever mitochondrial cell therapy trial for a mitochondrial disease, has been granted Fast-Track, Orphan Drug, and Rare Pediatric Disease designations by the FDA. Minovia will present case studies of patients treated with MAT at a conference in June. The company is also opening a U.S. operation in Cambridge, Massachusetts, to expand its clinical and research collaborations. John Cox has been appointed as chairman of the board. Pearson syndrome is a rare pediatric mitochondrial disease caused by a deletion in mitochondrial DNA.
Customers
